Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

NCT ID: NCT00672074

Last Updated: 2017-04-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if ipamorelin is safe and effective in the management of post-operative ileus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The safety and efficacy of ipamorelin in the management of post-operative ileus

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ileus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 Ipamorelin

Group Type ACTIVE_COMPARATOR

Ipamorelin

Intervention Type DRUG

IV

2 Placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ipamorelin

IV

Intervention Type DRUG

placebo

IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ST ST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* willing to comply with protocol
* undergoing bowel resection surgery
* ASA Class I-III
* Females must not be pregnant
* Body weight 40-150 kg

Exclusion Criteria

* mentally incompetent or unable to provide informed consent
* clinically unstable
* significant liver disease
* clinically significant lab or EKG abnormalities
* alcohol or illicit drug abuse
* history of or current surgery that would prevent proper evaluation of safety or efficacy of drug
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helsinn Therapeutics (U.S.), Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Suzan Allen

Role: STUDY_DIRECTOR

Helsinn Therapeutics (U.S.), Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

USC/Norris Cancer Center

Los Angeles, California, United States

Site Status

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

Palo Alto Veterans Hospital

Palo Alto, California, United States

Site Status

University of Colorado Hospital

Aurora, Colorado, United States

Site Status

Denver VA Hospital

Denver, Colorado, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Cleveland Clinic of Weston

Weston, Florida, United States

Site Status

St. Joseph's Hospital of Atlanta

Atlanta, Georgia, United States

Site Status

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

Indiana University Medical Center

Indianapolis, Indiana, United States

Site Status

Ochsner Medical Center

New Orleans, Louisiana, United States

Site Status

UMass Memorial Healthcare

Worcester, Massachusetts, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

Barnes Jewish Hospital

St Louis, Missouri, United States

Site Status

Stony Brook University Medical Center

Stony Brook, New York, United States

Site Status

The Christ Hospital

Cincinnati, Ohio, United States

Site Status

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Site Status

The Pennsylvania State University

Hershey, Pennsylvania, United States

Site Status

St. Joseph Hospital

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21.

Reference Type DERIVED
PMID: 25331030 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ST-IPAM-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Alvimopan Use in Polytraumatized Patients
NCT03068975 TERMINATED PHASE4
Prucalopride in Postoperative Ileus
NCT02947269 COMPLETED PHASE3
Gastrografin in Postoperative Ileus
NCT01648972 COMPLETED PHASE2/PHASE3